Oramed Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>OP</div>
ORMP -- USA Stock  

USD 5.53  0.95  20.74%

The underlying rationale for this short perspective is to recap Oramed as an investment oportunity for December. We will focus on why recent Oramed Pharmaceuticals price moves suggest a bounce in December.
Published over a month ago
View all stories for Oramed Pharmaceuticals | View All Stories
Estimating Oramed Pharmaceuticals (NASDAQ:ORMP) price for December 2020.
The company has a beta of 0.3939. Let's try to break down what Oramed's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Oramed Pharmaceuticals will likely underperform. The beta indicator helps investors understand whether Oramed Pharmaceuticals moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Oramed deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns.
There are currently many different techniques concerning forecasting the market as a whole as well as predicting future values of individual securities such as Oramed Pharmaceuticals. Regardless of method or technology, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.

Predictive Modules for Oramed Pharmaceuticals

Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Oramed Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Oramed Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Oramed Pharmaceuticals. Your research has to be compared to or analyzed against Oramed Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Oramed Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Oramed Pharmaceuticals.

How important is Oramed Pharmaceuticals's Liquidity

Oramed Pharmaceuticals financial leverage refers to using borrowed capital as a funding source to finance Oramed Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Oramed Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Oramed Pharmaceuticals's total debt and its cash.

How Oramed utilizes its cash?

To perform a cash flow analysis of Oramed Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Oramed Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Oramed Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

What is driving Oramed Pharmaceuticals Investor Appetite?

The recent price roll up of Oramed Pharmaceuticals may encourage insiders to take a closer look at the company as it is trading at a share price of 4.45 on 7,141,500 in trading volume. The company executives may have good odds in positioning the company resources to exploit market volatility in December. The stock standard deviation of daily returns for 30 days investing horizon is currently 6.46. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Oramed Pharmaceuticals partners.

Are Oramed Pharmaceuticals technical ratios showing a bounce-back?

Recent total risk alpha is at -0.41. Oramed Pharmaceuticals exhibits very low volatility with skewness of 0.67 and kurtosis of 1.82. However, we advise investors to further study Oramed Pharmaceuticals technical indicators to make sure all market info is available and is reliable.

Our Bottom Line On Oramed Pharmaceuticals

Although some firms within the biotechnology industry are still a little expensive, even after the recent corrections, Oramed Pharmaceuticals may offer a potential longer-term growth to insiders. The inconsistency in the assessment between current Oramed valuation and our trade advice on Oramed Pharmaceuticals is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Oramed Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Oramed Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com